(May 24, 2024, 11:04 AM EDT) -- WASHINGTON, D.C. — A professor researching the risk of sexual dysfunction after stopping selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) drugs filed a complaint asking a District of Columbia federal court to declare that the U.S. Food and Drug Administration failed to respond to a citizen petition requesting that the warning labels be changed and to order the FDA to issue a decision within 30 days....